Midstream energy partnerships and preferred stocks offer 7% yields, meeting retirement income targets the S&P 500 cannot match. A $475,000 portfolio targeting $33,600 in annual income requires a 7% yield, far above the S&P 500’s sub-2% average. Traditional index funds fall
American Resources Corp (NASDAQ:AREC) said on Wednesday it has completed a multi-year transformation away from metallurgical coal into a rare earth and critical mineral supply chain platform. As part of the restructuring, American Resources has separated its legacy coal op
Medicare expands coverage for Personalis' NeXT Personal minimal residual disease test, boosting potential U.S. market access. Personalis (PSNL) shares climbed approximately 5% in premarket trading after securing its fourth Medicare coverage decision for NeXT Personal, a mi
Uniqure NV targets UK regulatory approval for Huntington’s gene therapy AMT-130 in Q3 2026 after strong Phase 1/2 trial results. Uniqure NV (NASDAQ:QURE) shares have climbed 60% in the past month and over 100% year-to-date, driven by progress in its gene therapy pipeline.
Analysts project a 125% surge in Passage Bio shares over 12 months despite a 50% year-to-date decline. Passage Bio Inc (NASDAQ:PASG) has engaged Wedbush PacGrow as a financial advisor to explore strategic alternatives aimed at maximizing shareholder value. The move follows
Voyager Therapeutics plans FDA authorization request for its Alzheimer’s gene therapy VY1706 in Q2 2026 after positive preclinical results. Voyager Therapeutics (NASDAQ:VYGR) reported preclinical data showing its Alzheimer’s gene therapy, VY1706, reduced tau protein in non
Regenxbio Inc (NASDAQ:RGNX) is one of the best gene therapy stocks to buy in 2026. On May 14, Regenxbio reported its Q1 2026 financial results and provided operational updates The company exited the quarter with $150.5 million in cash. The management expects the cas
EVERTEC, Inc. (NYSE:EVTC) is one of the oversold software stocks to buy according to Wall Street analysts. On May 6, EVERTEC, Inc. (NYSE:EVTC) reported Q1 2026 results, with total revenue rising 8% year over year to $247.9 million and exceeding consensus estimates by 3.47%
Donnelley Financial Solutions, Inc. (NYSE:DFIN) is one of the oversold software stocks to buy according to Wall Street analysts. On May 5, Donnelley Financial Solutions, Inc. (NYSE:DFIN) reported its first-quarter 2026 financial results, where it posted total revenue of $2
Intellicheck, Inc. (NASDAQ:IDN) is one of the oversold software stocks to buy according to Wall Street analysts. On May 12, Intellicheck, Inc. (NASDAQ:IDN) announced its Q1 2026 financial results, reporting record quarterly revenue of $5.52 million, up 13% year over year</
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.